Sight Sciences, Inc. (SGHT)
| Market Cap | 598.59M +59.2% |
| Revenue (ttm) | 88.40M +16.2% |
| Net Income | -28.40M |
| EPS | -0.52 |
| Shares Out | 55.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 335,560 |
| Open | 10.48 |
| Previous Close | 10.49 |
| Day's Range | 10.44 - 10.87 |
| 52-Week Range | 3.38 - 11.60 |
| Beta | 2.40 |
| Analysts | Buy |
| Price Target | 12.25 (+13.74%) |
| Earnings Date | Nov 4, 2026 |
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and O... [Read more]
Financial Performance
In 2025, Sight Sciences's revenue was $77.36 million, a decrease of -3.13% compared to the previous year's $79.87 million. Losses were -$38.43 million, -25.40% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price target is $12.25, which is an increase of 13.74% from the latest price.
News
Sight Sciences price target raised to $13.50 from $8 at UBS
UBS raised the firm’s price target on Sight Sciences (SGHT) to $13.50 from $8 and keeps a Buy rating on the shares.
Sight Sciences Transcript: Stifel 2026 Healthcare Conference 2026
CMS set a $1,000 TearCare SmartLids supply-code price, supporting payer discussions; management expects additional coverage within quarters. TearCare remains early in a large market, while OMNI Ultra launches in Q4 2026 with a larger tailwind expected in 2027.
Sight Sciences to Present at Two Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences price target raised to $14 from $12 at Lake Street
Lake Street raised the firm’s price target on Sight Sciences (SGHT) to $14 from $12 and keeps a Buy rating on the shares following a top- and bottom-line beat and…
Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing inno...
Sight Sciences price target raised to $10 from $8 at Stifel
Stifel analyst Thomas Stephan raised the firm’s price target on Sight Sciences (SGHT) to $10 from $8 and keeps a Buy rating on the shares.
Sight Sciences price target raised to $12 from $9 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Sight Sciences (SGHT) to $12 from $9 and keeps an Overweight rating on the shares. The firm notes the…
Sight Sciences reports Q3 EPS (12c), consensus (12c)
Reports Q3 revenue $24.92M, consensus $23.51M. “We delivered another strong quarter with 25% total revenue growth, record IDE revenue, continued IG revenue growth, and a significant reduction in cash ...
Sight Sciences raises FY26 revenue view to $92M-$93M from $88M-$92M
Consensus $90.32M. The company said, “Sight Sciences (SGHT) raised its revenue guidance for full year 2026 to range from $92 million to $93 million, representing year-over-year growth of 19% to…
Sight Sciences Earnings Call Transcript: Q3 2026
Q3 revenue reached a record $24.9M, up 25% YoY, while cash use improved sharply. FY26 revenue guidance rose to $92M-$93M, with adjusted OpEx guidance maintained as TearCare and OMNI drive growth.
Sight Sciences Earnings release: Q3 2026
Sight Sciences released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Sight Sciences Quarterly report: Q3 2026
Sight Sciences has published its Q3 2026 quarterly earnings report on November 4, 2026.
Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences Slides: Investor presentation
Sight Sciences has posted slides in relation to its latest quarterly earnings report, which was published on November 4, 2026.
Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Sight Sciences (SGHT) with a Buy rating and $14 price target Sight is a medical device company focused on developing and commercializing interventional treatments...
Citi ups Sight Sciences target, opens ‘upside 90-day catalyst watch’
Citi raised the firm’s price target on Sight Sciences (SGHT) to $10 from $8 and keeps a Neutral rating on the shares. Citi also added an “upside 90-day catalyst watch”…
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
MENLO PARK, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, int...
Sight Sciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The business has shifted to a high-growth, dual-platform model with strong momentum in both glaucoma and dry eye interventions. Recent payer wins, product innovation, and operational discipline are driving revenue growth and expanding market access, with new product launches and pipeline developments expected in the next year.
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing inno...
Sight Sciences announces updated TearCare System Indications for Use
Sight Sciences (SGHT) announced that, effective August 18, the FDA updated the TearCare System Indications for Use to state: “The Sight Sciences TearCare System is a thermal-activated gland expression...
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologie...
Sight Sciences price target raised to $8 from $6 at Citi
Citi raised the firm’s price target on Sight Sciences (SGHT) to $8 from $6 and keeps a Neutral rating on the shares. The firm is more optimistic on the medical…
Sight Sciences price target raised to $8 from $7 at UBS
UBS raised the firm’s price target on Sight Sciences (SGHT) to $8 from $7 and keeps a Buy rating on the shares.
Sight Sciences reports Q2 EPS (8c), consensus (14c)
Reports Q2 revenue $23.39M, consensus $21.69M. “We delivered a strong second quarter, with revenue growth accelerating to 20% year-over-year, and both business segments contributing meaningfully to th...